MedPath

Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer

Not Applicable
Conditions
Prostate Cancer Recurrent
Stage II Prostate Carcinoma
Stage III Prostate Carcinoma
Interventions
Device: PET/MR
Registration Number
NCT01938339
Lead Sponsor
Seoul National University Hospital
Brief Summary

To development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (PET/MR) in prostate cancer

* to establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer

* to establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer and early detection of recurrent prostate cancer

Detailed Description

To establish the optimal imaging technique of PET/MR using multiple radioactive tracers for prostate cancer

* Recruiting 30 patients with prostate cancer ahead to radical prostatectomy

* PET/MR using 18F-choline with dedicated prostate MRI in all patients

* PET/MR using 18fluoride(F)-fluorodeoxyglucose(FDG)in all patients after 2-7 days

* PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR

* outcome assessment: comparison of scan time, image quality, tumor detection rate, standardized uptake values of lesions

* establishing optimal imaging technique for prostate PET/MR

To establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer

* comparison of findings on PET/MR, MRI and PET/CT with pathological mapping after radical prostatectomy

* outcome assessment: accuracy of PET/MR for localization and staging of prostate cancer compared with MRI only and PET/CT only

To establish the imaging biomarker using PET/MR for early detection of recurrent prostate cancer

* Recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or radiation therapy

* Recruiting 15 patients with treated prostate cancer without recurrence

* PET/MR using 18F-choline with dedicated prostate MRI in all patients

* PET/MR using 18F-FDG in all patients after 2-7 days

* PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR

* comparison of findings on PET/MR, MRI, and PET/CT with clinical data in two patient groups with or without recurrent prostate cancer

* outcome assessment: accuracy of PET/MR for early detection and localization of recurrent prostate cancer compared with MRI only and PET/CT only

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
60
Inclusion Criteria
  • patient with prostate cancer before treatment
  • patient with prostate cancer treated
  • patient with prostate cancer recurrent
Read More
Exclusion Criteria
  • patient with contraindication for MRI
  • Patient with severe renal impairment
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PET/MRPET/MRMulti-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
Primary Outcome Measures
NameTimeMethod
accuracy of PET/MR predicting localization and staging of prostate cancer1 week after radical prostatectomy

analysis of accuracy of PET/MR predicting localization and staging of prostate cancer by comparison of PET/MR findings with pathological mapping images after radical prostatectomy

Secondary Outcome Measures
NameTimeMethod
accuracy of early detection and localization of recurrent prostate cancer1 week after PET/MR imaging

accuracy of PET/MR for early detection and localization of recurrence by comparison of PET/MR findings with clinical data in two groups of patients with or without recurrent prostate cancer

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath